ORAL PRESENTATIONS

Oral Award Sessions

Oral Award Session I

072CLINICOPATHOLOGICAL AND MOLECULAR PROFILE OF BRAZILIAN PATIENTS WITH CUSHING SYNDROME DUE TO PRIMARY PIGMENTED MICRONODULAR ADRENAL HYPERPLASIAPDF
073ASSESSMENT OF TESTICULAR FUNCTION IN BOYS AND ADOLESCENTS WITH HEMATOLOGICAL MALIGNANCIES: PROSPECTIVE LONGITUDINAL STUDY FROM DIAGNOSIS UP TO 3 YEARS AFTER THE END OF CHEMOTHERAPYPDF
113COMPLETE 46,XY GONADAL DYSGENESIS: CLINICAL SPECTRUM, MOLECULAR ETIOLOGY, AND TUMOR OUTCOMES IN NINE PATIENTSPDF
138NOT ALL OBESITY AGES EQUALLY: EPIGENETIC RESILIENCE IN EARLY-ONSET OBESITY MEDIATED BY THE IGF-1/FGF-21 AXISPDF
178EARLY DETECTION OF PEDIATRIC METABOLIC SYNDROME USING RIAO AND MACHINE LEARNINGPDF

Oral Award Session II

038PEDIATRIC DIFFERENTIATED THYROID CARCINOMA IN PATIENTS WITH HEREDITARY TUMOR PREDISPOSITION SYNDROMESPDF
053IDIOPATHIC ADVANCED BONE AGE: EXPANDING THE GENETIC SPECTRUM BEYOND ACANPDF
065REDOX PATHWAY DYSREGULATION DEFINES TUMOUR AGGRESSIVENESS AND MITOTANE RESPONSE IN ADRENOCORTICAL TUMOURSPDF
150CLINICAL AND BIOCHEMICAL CLUES TO DIFFERENTIATE HEREDITARY HYPOPHOSPHATEMIC RICKETS WITH HYPERCALCIURIA (HHRH) FROM X-LINKED HYPOPHOSPHATEMIA (XLH) IN A PEDIATRIC COHORT WITH SLC34A3 VARIANTSPDF
164INDIRECT APPROACH TO ESTABLISH REFERENCE INTERVALS FOR THYROID HORMONES IN INFANTS UNDER ONE YEAR OF AGEPDF

Oral Presentations

Oral Presentation I

027SOMAPACITAN IN CHILDREN AND ADOLESCENTS WITH NOONAN SYNDROME: 2-YEAR REAL8 RESULTS INCLUDING SWITCH FROM DAILY GHPDF
054IDENTIFYING AN EPIGENETIC SIGNATURE FOR NOONAN SYNDROME AS A COMPLEMENTARY DIAGNOSTIC APPROACH.PDF
075A RANDOMIZED CONTROLLED TRIAL OF ORAL INFIGRATINIB IN CHILDREN WITH ACHONDROPLASIA: RESULTS FROM THE PROPEL 3 STUDYPDF
119CLINICAL IMPACT OF PROSPECTIVE EXOME SEQUENCING IN CHILDREN INITIALLY CLASSIFIED AS HAVING IDIOPATHIC SHORT STATUREPDF
131GROWTH PATTERNS AND TREATMENT-RELATED FACTORS IN CHILDREN WITH CONGENITAL ADRENAL HYPERPLASIA IDENTIFIED BY NEWBORN SCREENING IN SOUTHERN BRASILPDF
151SHORT STATURE ASSOCIATED WITH A SPLICING ACAN VARIANT: PHENOTYPIC SPECTRUM IN FOUR UNRELATED FAMILIESPDF

Oral Presentation II

060REAL-WORLD GLYCEMIC OUTCOMES OF THE MINIMED™ 780G ADVANCED HYBRID CLOSED-LOOP SYSTEM IN YOUNG CHILDREN AGED 2–6 YEARS: A CHILEAN REAL-WORLD ANALYSISPDF
090CARDIOMETABOLIC TRAJECTORY FROM ADOLESCENCE TO ADULTHOOD IN CLASSIC CONGENITAL ADRENAL HYPERPLASIA: IMPACT OF HORMONAL CONTROLPDF
130PEDIATRIC OBESITY ONSET DRIVES MORE SEVERE MOLECULAR AGING THAN ADULT-ONSET ADIPOSITY: A BIRTH COHORT STUDY ON BIOLOGICAL EMBEDDINGPDF
139ADVERSE CHILDHOOD EXPERIENCES AMPLIFY IMMUNO-METABOLIC RISK DEPENDING ON LONGITUDINAL BMI TRAJECTORIES: A PRINCIPAL COMPONENT AND INTERACTION ANALYSISPDF
141EVIDENCE OF A LASTING PROTECTIVE LEGACY AFTER REVERSAL OF CHILDHOOD OBESITY DURING PUBERTY: A LONGITUDINAL ANALYSIS OF SUBCLINICAL CARDIOVASCULAR RISKPDF
172STEROID PROFILING BY ULTRA-HIGH-PERFORMANCE LIQUID CHROMATOGRAPHY–TANDEM MASS SPECTROMETRY (UHPLC–MS/MS) FOR THE ASSESSMENT OF HYPERANDROGENEMIA IN ADOLESCENTS WITH POLYENDOCRINE METABOLIC OVARIAN SYNDROME (PMOS).PDF

Oral Presentation III

023CHANGES IN THYROID HORMONES DURING THE ONSET AND PROGRESSION OF PUBERTY. IS IT NECESSARY TO SEPARATE BY SEX TO ESTABLISH REFERENCE RANGES?PDF
024MACROPROLACTINEMIA SCREENING REQUEST IN CHILDREN AND ADOLESCENTS AT A TERTIARY CARE HOSPITAL: A 10-YEAR RETROSPECTIVE STUDYPDF
064IMPACT OF HIGH DHEAS AT ADRENARCHE ON AGE OF PUBERTAL DEVELOPMENT AND ANTHROPOMETRY IN MALE PATIENTSPDF
074LONGER-TERM EFFICACY AND SAFETY RESULTS OF INFIGRATINIB IN CHILDREN WITH ACHONDROPLASIAPDF
087MOLECULAR DIAGNOSES OF X–LINKED HYPOPHOSPHATEMIA FROM A MULTI- COUNTRY SPONSORED GENETIC TESTING PROGRAM IN LATIN AMERICAPDF
115SAFETY AND EFFICACY OF TWELVE-WEEKLY TESTOSTERONE UNDECANOATE IN MALE ADOLESCENTS WITH HYPOGONADISM: A MULTICENTRE PILOT CLINICAL TRIALPDF

Oral Presentation IV

043ENDOCRINE DYSFUNCTION AFTER TBI-BASED ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION IN PEDIATRIC ALLPDF
057PUBERTAL GONADAL FUNCTION IN 45,X/46,XY CHROMOSOMAL MOSAICISM. EXPLORING PREDICTIVE VALUE OF MINIPUBERTAL DATA.PDF
094BEYOND 21-HYDROXYLASE DEFICIENCY: RARE SALT-WASTING DISORDERS IN A HISTORICAL COHORT FROM A TERTIARY CENTERPDF
103POSTSURGICAL HYPOPARATHYROIDISM IN PEDIATRIC DIFFERENTIATED THYROID CANCER: INCIDENCE, CLINICAL COURSE, AND ASSOCIATED RISK FACTORSPDF
118DIFFERENTIATED THYROID CARCINOMA IN CHILDHOOD CANCER SURVIVORS: A SINGLE-CENTER EXPERIENCEPDF

Information

SLEP, the Latin American Society of Pediatric Endocrinology was founded in 1986 under the leadership of César Bergadá. The main objective of the society is to integrate pediatric endocrinologists, biochemists, pediatricians, endocrinologists or professionals from similar areas for the development of pediatric endocrinology in the broadest sense in Latin America.

Contact

For registration related queries please contact:
slep-registration@wearemci.com

For general congress inquiries: slep@wearemci.com

Español English Portugues